Unlocking the Vault: Can Japan's World-Class Science Finally Scale to Global Biotech Success?

Japan possesses some of the most advanced scientific research in the world, yet it has historically struggled to translate this academic brilliance into globally dominant biotechnology giants. To understand this paradox and explore the winds of change sweeping the sector, a high-profile panel of industry leaders recently convened to discuss Japan's growth strategies.

The discussion featured Jun Hashimoto, Partner at venture capital firm AN Venture Partners; Mr. Shino from the Alliance Management Office of Shionogi & Co., Ltd.; Ms. Chieko Mori, President and CEO of the University of Tokyo-originated biotech company Senno Therapeutics Inc.; and Mr. Ura of the Cabinet Office’s Office of Health and Medical Strategy. Together, they mapped out the structural bottlenecks holding Japan back and the massive public and private shifts aiming to catapult Japanese biotechnology onto the global stage.

The Paradox: World-Class Science, Missing Startups

Japan’s foundational scientific capability is undeniably elite, but a stark disconnect remains between research strength and commercial biotech outcomes.

• Elite Scientific Foundations: Japan has produced a significant number of Nobel laureates in the natural sciences and remains one of the world’s leading research nations. Furthermore, the Tokyo–Yokohama region ranks among the world’s leading innovation and patent-filing clusters.

• A Track Record of Blockbusters: Japanese research has birthed globally recognized, multi-billion-dollar blockbusters. These include the cancer immunotherapy Opdivo (pioneered by Kyoto University’s Prof. Tasuku Honjo), the cholesterol-lowering medication Crestor (developed by Shionogi), and the rheumatoid arthritis treatment Actemra (originated by Osaka University's Prof. Tadamitsu Kishimoto and developed by Chugai).

• The Startup Deficit: Despite these breakthroughs, very few global drugs originate from Japanese startups. In the United States, startups originate a large share of new drug candidates and approved medicines, often partnering with or being acquired by larger pharmaceutical companies. According to data presented during the session, startups originated over 80% of newly approved drugs in the US, whereas the corresponding figure for domestic drug approvals in Japan stood at approximately 7%, with Japanese startup-originated drugs remaining extremely rare among US approvals.

The Structural Bottlenecks

The panelists identified three deeply interconnected hurdles that have historically stifled Japan's biotech ecosystem: a chronic funding gap, extreme risk aversion in talent, and domestic market constraints.

The Chronic Funding Gap

Japan's annual venture capital funding flowing into pharmaceutical startups hovers at just 20 to 30 billion yen—less than 1% of the capital deployed in the US biotech market. Because drug development is an ultra-high-risk, capital-intensive process—taking 10 to 15 years, costing tens to hundreds of billions of yen, and carrying a meager 10% clinical success rate—this funding gap severely limits the number of candidates Japan can advance.

The Talent and Risk Barrier

Unlike in the US, where fluid movement between academia, venture capital, and industry is common, Japanese pharmaceutical talent rarely migrates to startups. Major Japanese pharmaceutical companies offer highly stable, well-compensated environments to pursue research. Moving to a pre-clinical startup represents an extraordinary psychological hurdle. Ms. Chieko Mori, who built her career at Astellas Pharma before becoming President and CEO of Senno Therapeutics, recalled feeling physically shaken when she decided to leave a stable corporate career for a startup.

Market Pricing Pressure

The global pharmaceutical profit pool is heavily concentrated in the US. Some estimates suggest that the US accounts for roughly three-quarters of global pharmaceutical profits. This dominance is driven by the fact that US drug prices can be several times higher than those in Japan, depending on the product and pricing measure, alongside pricing models where US drug prices can rise annually while Japanese prices are systematically cut. Consequently, Japanese biotechs must target the US market from day one to deliver viable investment returns.

Additionally, discussions regarding policy shifts like the US Most Favored Nation (MFN) drug pricing proposal have raised concerns in Japan. If Japanese drug prices are kept exceptionally low, global pharmaceutical firms may delay or bypass launching innovative therapies in Japan altogether—a phenomenon known as drug lag or drug loss.

The Winds of Change: Government Support and Global Inflow

Despite these historical barriers, Japan is entering an unprecedented era of transformation, propelled by aggressive government incentives and a sudden influx of international venture capital.

Government Support Enters a New Phase

The Japanese government has officially designated "drug discovery and advanced medicine" as one of its 17 national core growth strategy areas.

• The CAGR Gap: During the strategy discussions, policymakers highlighted that while the global patented drug market has been growing at a compound annual growth rate (CAGR) of 9.6%, Japan's market growth sat at 5.3%. The new strategy aims to expand Japan’s domestic market in line with global growth trends by facilitating the entry of innovative therapies.

• The AMED Catalyst: To bridge the early-stage funding "valley of death," the Agency for Medical Research and Development (AMED) launched a 350-billion-yen Drug Discovery Venture Ecosystem program.

• Project Support Structure: Under this initiative, certified venture capital investors must contribute at least one-third of eligible project costs, while AMED may provide subsidies covering up to two-thirds. Selected projects—including pre-clinical assets transitioning through Proof of Concept (POC)—may have eligible development budgets of up to approximately ¥10 billion, with AMED covering up to two-thirds of those eligible costs. Senno Therapeutics was selected as a recipient in the program's tenth round.

Global Investors Back Japanese-Origin Science

Foreign capital is actively backing Japanese scientific innovations. Currently, this often occurs through a "hybrid" model where companies leverage Japanese technology but headquarter themselves in the US to recruit global management talent and access the FDA. High-profile examples include:

• City Therapeutics: Founded on RNA interference (RNAi) technology from Prof. Yukihide Tomari (University of Tokyo) and Prof. Kotaro Nakanishi (Ohio State University). The company launched with a $135 million Series A financing (equivalent to roughly ¥20 billion depending on the exchange rate), backed by ARCH Venture Partners, Fidelity, and AN Venture Partners. It later raised $99.5 million in Series B financing, with Viking Global Investors and Sofinnova Investments joining the investor syndicate.

• Crystalys Therapeutics: A company created around rights carved out from Fuji Yakuhin. The startup launched with a $205 million Series A financing and is currently running Phase III clinical trials directly in the US.

• Shinobi Therapeutics: Spun out of Kyoto University's cell therapy research, the startup raised a $51 million Series A led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan.

The "Inversion" Debate

This hybrid structure, sometimes called corporate inversion—where a startup built on Japanese intellectual property establishes its headquarters, executive team, and IP registration in the US—presents a complex dilemma. While some worry about local value creation, both Jun Hashimoto and Mr. Ura noted that under current conditions, registering under US corporate law and hiring management experienced in FDA approvals is often necessary to secure top-tier US venture capital and maximize the probability of clinical success. However, they emphasized that as these hybrid startups achieve high-profile exits, global investors will gain confidence in Japanese science, eventually making them comfortable investing directly in Japan-domiciled entities.

The Road Ahead: Establishing the Virtuous Cycle

To enable more companies built on Japanese science to retain meaningful operations and value creation in Japan, the domestic ecosystem must build a self-sustaining loop. Rather than viewing biotech as a series of isolated transactions, the panelists outlined a continuous, four-step Virtuous Cycle required to anchor Japanese innovation:

Achieving a Successful Global Exit

The cycle begins with a Successful Global Exit. In the biotechnology sector, this typically occurs when a startup goes public through an IPO or is acquired by a major pharmaceutical corporation through mergers and acquisitions. In mature hubs like Boston and San Francisco, massive historic exits—such as Takeda acquiring Millennium or Roche acquiring Genentech—served as the primary catalysts for their local ecosystems.

When a Japanese biotech startup achieves a high-profile global exit, it proves to international venture capitalists and institutional investors that Japanese scientific assets are highly lucrative, attracting deeper pools of global capital. It also provides a concrete precedent, proving to domestic researchers and business leaders that joining a startup is a viable, highly rewarding career path rather than an unstable risk.

Reinvesting Royalties and Capital into Universities

Once a global exit or major commercial milestone is achieved, it triggers a critical flow of capital back to its source: Reinvesting Royalties and Capital into Universities.

Because most biotech breakthroughs originate in academic laboratories, the licensing agreements signed by these startups ensure that a successful drug launch or acquisition returns substantial wealth to the universities in the form of royalties and milestone payments. This newly injected capital is then used by universities to fund the next generation of basic research, buy state-of-the-art laboratory equipment, and spin out new startup seeds, ensuring the scientific pipeline never runs dry.

Attracting Experienced Executive Talent

With university research heavily funded and startup success stories validated, the ecosystem can finally solve one of Japan's steepest bottlenecks: Attracting Experienced Executive Talent.

While Japan has an abundance of brilliant laboratory researchers, it historically lacks experienced business executives who know how to build a company, negotiate global deals, and secure venture funding. A thriving ecosystem with proven exit pathways lowers the psychological barriers for highly stable, risk-averse employees at major domestic pharmaceutical firms to transition into startups. As seasoned executives jump to startups, they bring crucial drug development expertise, global networks, and operational wisdom to early-stage ventures.

Securing Active Pharmaceutical Partnerships

Equipped with top-tier management talent, startups can successfully negotiate and execute Active Pharmaceutical Partnerships.

Biotech startups excel at innovative, early-stage biology, but they rarely have the massive resources required to handle the complex physical scaling of a drug. This is where big pharma partners step in, particularly in the realm of Chemistry, Manufacturing, and Controls (CMC).

For example, Shionogi's newly established Alliance Management Office works closely with biotech partners post-contract to provide hands-on technical and operational support. In one instance, a biotech partner developed a highly promising Phase I asset with exceptional safety and efficacy, but the drug substance could only be stored at ultra-low, sub-zero temperatures, severely limiting its clinical viability and global distribution. By stepping in to manage the CMC portion, Shionogi helped optimize the physical drug product, combining the startup’s agile science with big pharma’s manufacturing and clinical infrastructure. These robust partnerships steer therapeutic assets through clinical trials, ultimately paving the way for the next Successful Global Exit—completing the loop and spinning the wheel of the ecosystem faster.

Conclusion

As Mr. Ura of the Cabinet Office concluded, Japan’s biotech startup ecosystem is beginning to move from policy ambition toward tangible execution. The challenge now is execution: ensuring Japanese startups deliver rigorous clinical data, attract global management talent, and establish Japan as a premier launchpad for the world's next generation of life-saving medicines.